1. Home
  2. DGII vs JANX Comparison

DGII vs JANX Comparison

Compare DGII & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$42.52

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.88

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
JANX
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DGII
JANX
Price
$42.52
$13.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$48.80
$60.27
AVG Volume (30 Days)
300.2K
2.3M
Earning Date
02-04-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
77.05
N/A
EPS
1.08
N/A
Revenue
$430,221,000.00
$10,000,000.00
Revenue This Year
$10.51
N/A
Revenue Next Year
$8.01
N/A
P/E Ratio
$39.67
N/A
Revenue Growth
1.46
N/A
52 Week Low
$22.39
$13.26
52 Week High
$48.00
$61.59

Technical Indicators

Market Signals
Indicator
DGII
JANX
Relative Strength Index (RSI) 45.36 31.15
Support Level $42.48 $13.26
Resistance Level $45.13 $14.30
Average True Range (ATR) 1.21 0.44
MACD -0.39 0.44
Stochastic Oscillator 8.14 47.58

Price Performance

Historical Comparison
DGII
JANX

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: